Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Real-World Study of Alternating Hepatic Arterial Infusion Chemotherapy and Systemic Chemotherapy With or Without Adebrelimab and Apatinib in Patients With Unresectable Biliary Tract Cancer

NCT07569679 is registered in ClinicalTrials.gov with Air Force Military Medical University, China as lead sponsor.

NCT NCT07569679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Real-World Study of Alternating Hepatic Arterial Infusion Chemotherapy and Systemic Chemotherapy With or Without Adebrelimab and Apatinib in Patients With Unresectable Biliary Tract Cancer
Lead sponsor
Air Force Military Medical University, China
Phase
Phase 2
Overall status
Recruiting
Start date
December 10, 2025
Completion date
December 30, 2028
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer